Review Article - (2017) Volume 3, Issue 2
Clinical Implications of Anti-CD19 Chimeric Antigen Receptors (CAR) T Cell Therapy in Acute Lymphoblastic Leukemia (ALL)
- Ali R Jazirehi1*, Tam N M Dinh1, Zena Taraporewalla1, Jahzeel L Paguntalan1 and Gary J Schiller2
- 1Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, USA
- 2Division of Hematology/Oncology, Department of Medicine, The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA
*Corresponding Author:
Ali R Jazirehi, Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, USA
Email: